about
Gait analysis and the cumulative gait index (CGI): Translational tools to assess impairments exhibited by rats with olivocerebellar ataxia.An open-label pilot trial of minocycline in children as a treatment for Angelman syndromeEthanol conditioned place preference and alterations in ΔFosB following adolescent nicotine administration differ in rats exhibiting high or low behavioral reactivity to a novel environment.Analysis of gait in rats with olivocerebellar lesions and ability of the nicotinic acetylcholine receptor agonist varenicline to attenuate impairmentsNeuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxiaPotential Use of Nicotinic Receptor Agonists for the Treatment of Chemotherapy-Induced Cognitive Deficits.Obstacles and Opportunities for Cholinergic Drug Development in the Treatment of Cognitive Disorders.Repeated ethanol exposure during adolescence alters the developmental trajectory of dopaminergic output from the nucleus accumbens septi.Stereotaxic localization of the developing nucleus accumbens septi.Dependence of adolescent novelty-seeking behavior on response phenotype and effects of apparatus scaling.An animal model of sensation seeking: the adolescent rat.The need to expand access to electroconvulsive therapy: a retrospective analysis of a new academic service.Repeated cocaine exposure: effects on catecholamines in the nucleus accumbens septi of periadolescent animals.Postpartum depression in rats: differences in swim test immobility, sucrose preference and nurturing behaviors.Effects of nicotine exposure on locomotor activity and pCREB levels in the ventral striatum of adolescent rats.Grid crossing: inability to compare activity levels between adolescent and adult rats.Doxorubicin and cyclophosphamide lead to long-lasting impairment of spatial memory in female, but not male mice.Cocaine reward and MPTP toxicity: alteration by regional variant dopamine transporter overexpression.Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors
P50
Q34266547-A4B99837-6B4B-41FA-800E-242BC3263EB1Q34769566-8A0FDC41-BE9A-49FD-86A7-6B05B220A210Q35687882-3112D8CA-236B-420E-B6CE-2E29282CF0C3Q35836503-55800A0E-5FF7-45BB-A802-E4F9D911026AQ37154555-8CAF09F0-A74B-4F42-A011-C856A59FE0E0Q38344507-BD2339EC-DB04-4BA9-8119-F3AED2AE92DFQ38714467-F869E10C-4CDB-46D3-B397-6DDB31DFD9D0Q43284743-2449EA17-78F8-463E-AACC-F323BB85F3F5Q43737486-6A495657-72AC-491D-A9C8-8F57F262B1F4Q44076217-804825EB-D5F4-43A4-B849-6DFDA039EC50Q44976768-9799650A-3B70-4E9B-A808-09D679AD3194Q48252211-8E7DB7E8-B906-4679-B616-F77F712D9DB5Q48262274-E423E148-3CFB-436B-8BD4-64C38258B23BQ48262958-64444F9C-B976-4BCE-B52A-2E1DBC28BBB7Q48678862-E9A4FD74-90D8-4EF0-92F4-E708699316B2Q48963082-DABF575F-8AD7-4102-80CB-A3CCDF924FA9Q50520026-896306E4-6BAB-4F15-BEFD-B0C7EFC67EBBQ51430696-BD714B78-E2D6-4026-ACD2-407B7216ED08Q91856994-2D48872D-47E6-444B-AB11-B1298C3CE2BD
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Rex M Philpot
@es
Rex M. Philpot
@en
Rex M. Philpot
@nl
Rex M. Philpot
@sl
type
label
Rex M Philpot
@es
Rex M. Philpot
@en
Rex M. Philpot
@nl
Rex M. Philpot
@sl
prefLabel
Rex M Philpot
@es
Rex M. Philpot
@en
Rex M. Philpot
@nl
Rex M. Philpot
@sl
P106
P1153
23966896400
P21
P31
P496
0000-0001-9107-3034
P569
2000-01-01T00:00:00Z